Mineralys Therapeutics, Inc. Common Stock (MLYS) is a publicly traded Healthcare sector company. As of May 20, 2026, MLYS trades at $28.45 with a market cap of $2.18B and a P/E ratio of -12.11. MLYS moved +9.30% today. Year to date, MLYS is -20.27%; over the trailing twelve months it is +76.58%. Its 52-week range spans $8.24 to $47.65. Analyst consensus is strong buy with an average price target of $51.17. Rallies surfaces MLYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for MLYS shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $28.45 |
| Market Cap | $2.18B |
| P/E Ratio | -12.11 |
| EPS | $-2.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $47.65 |
| 52-Week Low | $8.24 |
| Volume | 4.05M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-154.65M |
| Gross Margin | 0.00% |
8 analysts cover MLYS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $51.17.